Table 2.

Transcript levels of var subtype in children hospitalized with malaria

Primer domain subclassDCGroupUncomplicated (95% confidence interval) (n = 40)Severe anemia (95% confidence interval) (n = 46)PCerebral malaria (95% confidence interval) (n = 30)PRespiratory distress (95% confidence interval) (n = 18)PDied (95% confidence interval) (n = 9)P
DBLa1.1DC1A1 (1–1.5)1 (1–2.4)0.38741.4 (1–2.8)0.08981 (1–2.9)0.39191.1 (1–2.4)0.6591
var2csaDC2E4.7 (1.8–8.2)2.3 (1.4–3.5)0.22833.4 (1–9)0.52751.7 (1–3.6)0.09951 (1–5.1)0.0727
DBLe8DC3A1 (1–1)1 (1–1)0.10961 (1–1)0.28451 (1–1.3)0.27971 (1–2.7)0.2676
DBLb7 and 9DC5A1 (1–1)1 (1–1)0.48091 (1–1)0.83151 (1–1)0.66461 (1–1)0.4681
DBLgDC5A1 (1–1)1 (1–1)0.25891 (1 1.4)0.04071 (1–1.3)0.39941 (1–1)0.6883
DBLz5DC6B(A/C)1 (1–1.6)1 (1–1.4)0.90751.1 (1–6.1)0.11193.3 (1–6.5)0.15981 (1–7.8)0.9769
DBLgDC6B(A/C)1 (1–1.2)1 (1–2.3)0.43871.1 (1–3.5)0.10281.3 (1–3.4)0.22151 (1–4.4)0.9032
DBLe2DC7B(C)1 (1–1)1 (1–1)0.86441 (1–1)0.17241 (1–1)0.09441 (1–1.4)0.9016
DBLe3DC7B(A/C)1 (1–1)1 (1–1)0.82621 (1–1)0.78861 (1–1)0.56081 (1–2.3)0.9577
DBLa_CIDRaDC8B1 (1–1.1)3.5 (1–7.5)0.00032.8 (1–6.5)0.00694.4 (1–8.3)0.00871 (1–3.4)0.6422
DBLg4/6DC8B1 (1–1.7)5 (1.3–10.3)0.00212.4 (1–10.7)0.00793.1 (1.2–14.2)0.00621.1 (1–8.3)0.5571
CIDRa1.1DC8B1.1 (1–3.2)18.2 (7.8–29.4)0.000216.7 (7.6–30)0.00037.6 (2.3–31.6)0.01071.6 (1–31.4)0.6601
DBLb12 and DBLb3/5DC8B/A7.3 (1.1–13.2)28 (15.7–35.2)0.000423.3 (3.4–54.2)0.042812.8 (1.2–46)0.277217.7 (1–56.6)0.3291
DBLz4DC9B1.6 (1–4.1)1 (1–1.2)0.02141 (1–2)0.13441 (1–2.5)0.03741 (1–5.9)0.4616
DBLg of DC9DC9B1 (1–1.2)1 (1–1)0.00311 (1–1)0.10521 (1–1)0.23431 (1–1)0.1007
DBLz6DC10B1 (1–1)1 (1–1)0.88651 (1–1)0.74691 (1–1)0.38171 (1–1)0.3963
DBLe12DC12B/A1 (1–1)1 (1–1)0.61361 (1–1)0.18651 (1–1)0.21981 (1–1)0.0519
DBLa1.7DC13A1.2 (1–3)1.7 (1–9.8)0.32222 (1–31.7)0.17553.6 (1–11.5)0.41691 (1–35.2)0.7604
CIDRa1.4DC13A1 (1–1)1 (1–1)0.00181 (1–1.4)0.00061 (1–1.4)0.0041 (1–2.8)0.0028
DBLa1.5/6aDC16A1.1 (1–2.4)1.5 (1–2.8)0.73571 (1–3.1)0.95931 (1–1.5)0.19081 (1–1.6)0.1702
DBLa1.5/6bDC16A3 (1–5.7)3.3 (1–5.5)0.80233.8 (1–15.8)0.56281 (1–3.8)0.10322.8 (1–4.8)0.4994
CIDRdDC16A1 (1–1.7)1.1 (1–3.1)0.25621.7 (1–8.9)0.17191 (1–4.6)0.88281 (1–2.5)0.5288
DBLa0.16DC19B1 (1–1.5)1.5 (1–2.5)0.23492.2 (1.1–4.2)0.01771.8 (1.1–6)0.03823.4 (1–5.2)0.0476
CIDRa3.4DC19B/C3.2 (1.6–4.8)1.8 (1.1–3)0.39114.8 (2;9.9)0.26234.2 (1.4–9.8)0.43462 (1–9)0.6382
DBLa0.9DC20B1.1 (1–2.2)1 (1–2)0.91231 (1–1.8)0.58041 (1–1.7)0.31091 (1–5.9)0.5756
DBLa2/a1.1/2/4/7A18.9 (5.5–26.3)58.4 (33.2–77.1)0.000251.1 (23.6–101.3)0.004132.7 (12.2–71.9)0.087832.7 (1.8–79.2)0.5099
DBLa1.4A1 (1–1)1 (1–1)0.36811 (1–1.7)0.0631 (1–1.2)0.44651 (1–1)0.4676
CIDRa1.6A1 (1–1)1 (1–1)0.68351 (1–1)0.02461 (1–1)0.10871 (1–27.4)0.0208
CIDRa1.7A1 (1–1.6)1 (1–3.4)0.58771 (1–3.5)0.8161 (1–5.2)0.87581 (1–1)0.1141
CIDRa1.4 and CIDRa1A1 (1–1.3)1.8 (1–4.5)0.09581.9 (1–10.3)0.11991 (1–5.4)0.65521 (1–4.2)0.6848
DBLa0.6/9B1 (1–3.5)1.5 (1–3.2)0.95311.8 (1–2.5)0.95471.1 (1–2.3)0.52041 (1–4.7)0.5661
DBLb3A1 (1–3.1)2.8 (1.2–10)0.04367.9 (1–16.8)0.02874.5 (1–20)0.13532.6 (1–9.1)0.3779
DBLa1 not var3A13.3 (5.1–21.9)43.6 (33.4–63.8)065.1 (38.9–86)0.000132 (17.9–85.3)0.021818.4 (4–102.2)0.2642
DBLg9A/B/C1 (1–1)1 (1–1)0.71181 (1–1)0.92541 (1–1)0.9151 (1–2.7)0.2514
CIDRg1/2B1 (1–1)1 (1–1)0.85511 (1–1)0.27041 (1–1)0.56081 (1–1)0.399
DBLa0.1B1 (1–1)1 (1–1)0.42241 (1–1)0.7661 (1–1)0.39941 (1–1)0.4445
CIDRa2.2B1 (1–1)1 (1–1.4)0.27351 (1–1.6)0.49511 (1–2)0.93341 (1–2.7)0.7956
CIDRa2.3/5/6/7/9/10B3.6 (2.4–5.3)4.1 (2.4–8.9)0.64053.7 (1–8.5)0.47867.2 (1.9–14.1)0.35263.4 (1–13.4)0.6211
CIDRg2/9B1 (1–1)1 (1–1)0.55431 (1–1)0.92151 (1–1)0.81871 (1–2.5)0.7096
DBLb5B(A/C)1 (1–1)1 (1–2.6)0.04771 (1–1.1)0.37181.3 (1–4.3)0.01181.4 (1–3.2)0.0577
CIDRgB/C9.7 (3.9–19.7)8.5 (6.7 16.7)0.690210 (5.7–18)0.73047.8 (4.4–22.8)0.8735.4 (1.1–19.7)0.415
CIDRa3.1–3B/C1 (1–1)1 (1–1.6)0.04011.1 (1–2.4)0.04721.5 (1–2.7)0.04971.6 (1–7.3)0.1066
  • Transcript levels [median Tu level (95% confidence interval)] of var subtype in hospitalized patients with uncomplicated malaria; in patients diagnosed with severe anemia, cerebral malaria, or respiratory distress; or in patients who died from malaria. All P values are calculated by comparison of the severe syndrome group to the uncomplicated malaria patient group using the Wilcoxon rank sum test.